文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

抗干扰素α受体1抗体减轻失血性休克后的炎症与器官损伤

Anti-interferon-α receptor 1 antibodies attenuate inflammation and organ injury following hemorrhagic shock.
PubMed 文献 · J Trauma Acute Care Surg · 2019-01-01
一句话结论小鼠失血性休克模型中,抗IFNAR1抗体可降低血清器官损伤标志物并减轻肺、肝炎症与形态损伤。

本研究为转化动物模型研究,使用雄性C57BL/6小鼠(20-25 g)经股动脉控制性放血使平均动脉压维持在27 ± 2.5 mm Hg持续90分钟,随后用含1 mg/kg体重抗IFNAR1抗体或对照同型IgG的乳酸林格液(两倍失血量)复苏30分钟。复苏后20小时采集血和组织样本分析。结果显示HS后肺和肝中IFN-α与IFN-β mRNA显著升高;与IgG对照相比,IFNAR1-Ab治疗显著降低血清器官损伤标志物乳酸脱氢酶和天冬氨酸氨基转移酶,改善肺和肝形态完整性,并降低肺中促炎细胞因子TNF-α、IL-6蛋白水平及趋化因子MCP-1、MCP-2、MIP-2、KC的mRNA表达,同时降低肺髓过氧化物酶活性和凋亡细胞数。作者结论认为I型IFN信号通路可能是减轻HS患者器官功能障碍的潜在治疗靶点。

要点

  • 雄性C57BL/6小鼠(20-25 g)经股动脉控制性放血维持平均动脉压27 ± 2.5 mm Hg持续90分钟,建立失血性休克模型。
  • 复苏用两倍失血量乳酸林格液,其中含1 mg/kg体重抗IFNAR1抗体或对照同型IgG,复苏30分钟。
  • HS后肺和肝中IFN-α与IFN-β mRNA表达显著升高。
  • 与IgG对照相比,IFNAR1-Ab显著降低血清乳酸脱氢酶和天冬氨酸氨基转移酶水平,并改善肺和肝形态完整性。
  • IFNAR1-Ab降低肺中TNF-α、IL-6蛋白及MCP-1、MCP-2、MIP-2、KC mRNA表达,并减少肺髓过氧化物酶活性和凋亡细胞数。

适用人群与场景

  • 雄性C57BL/6小鼠,体重20-25 g,用于失血性休克转化动物模型研究。

处置流程与药物剂量

  • 经股动脉控制性放血使平均动脉压维持在27 ± 2.5 mm Hg持续90分钟以建立失血性休克。
  • 放血后复苏30分钟,使用两倍失血量体积的乳酸林格液,其中含1 mg/kg体重的抗IFNAR1抗体或对照同型IgG。
  • 复苏后20小时采集血和组织样本进行分析。

研究设计与关键结果

  • 研究类型为转化动物模型;雄性C57BL/6小鼠(20-25 g)经股动脉控制性放血维持平均动脉压27 ± 2.5 mm Hg持续90分钟,随后用两倍失血量乳酸林格液(含1 mg/kg体重抗IFNAR1抗体或对照同型IgG)复苏30分钟,复苏后20小时采样分析。
  • HS后小鼠肺和肝中IFN-α与IFN-β mRNA表达显著升高。
  • 与IgG对照相比,IFNAR1-Ab治疗显著降低血清乳酸脱氢酶和天冬氨酸氨基转移酶水平,并改善肺和肝形态完整性。
  • 与IgG对照相比,IFNAR1-Ab治疗显著降低肺中TNF-α和IL-6蛋白水平以及MCP-1、MCP-2、MIP-2、KC的mRNA表达。
  • 与IgG对照相比,IFNAR1-Ab治疗降低肺髓过氧化物酶活性和凋亡细胞数。

证据类型、等级与局限

  • 证据类型:转化动物模型研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为I型IFN信号通路可能是减轻失血性休克患者器官功能障碍的潜在治疗靶点。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Hemorrhagic shock (HS) is a life-threatening condition resulting from rapid and significant loss of intravascular volume, leading to hemodynamic instability and death. Inflammation contributes to the multiple organ injury in HS. Type I interferons (IFNs), such as IFN-α and IFN-β, are a family of cytokines that regulate the inflammatory response through binding to IFN-α receptor (IFNAR) which consists of IFNAR1 and IFNAR2 chains. We hypothesized that type I IFNs provoke inflammation and worsen organ injury in HS.

METHODS: Male C57BL/6 mice (20-25 g) underwent hemorrhage by controlled bleeding via the femoral artery to maintain a mean arterial pressure of 27 ± 2.5 mm Hg for 90 minutes, followed by resuscitation for 30 minutes with two times shed blood volume of Ringer's lactate solution containing 1 mg/kg body weight of anti-IFNAR1 antibody (Ab) or control isotype-matched IgG (IgG). Blood and tissue samples were collected at 20 hours after the resuscitation for various analyses.

RESULTS: The expression of IFN-α and IFN-β mRNAs was significantly elevated in lungs and liver of the mice after HS. The IFNAR1-Ab treatment significantly decreased serum levels of organ injury markers lactate dehydrogenase and aspartate aminotransferase, as well as improved the integrity of lung and liver morphology, compared to the IgG control. The protein levels of proinflammatory cytokines TNF-α and IL-6, and mRNA expression of proinflammatory chemokines monocyte chemoattractant protein (MCP)-1, MCP-2, macrophage inflammatory protein 2 (MIP-2), and keratinocyte cytokine (KC) in the lungs of the HS mice were significantly decreased after treated with IFNAR1-Ab. Moreover, the myeloperoxidase activity and number of apoptotic cells in the lungs of HS mice treated with IFNAR1-Ab were decreased in comparison to the IgG control.

CONCLUSION: Administration of IFNAR1-Ab reduces inflammation and tissue injury. Thus, type I IFN signaling may be a potential therapeutic target for mitigating organ dysfunction in patients suffering from HS.

STUDY TYPE: Translational animal model.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Cagliani J, Yang WL, McGinn JT, et al. Anti-interferon-α receptor 1 antibodies attenuate inflammation and organ injury following hemorrhagic shock. J Trauma Acute Care Surg. 2019. PMID: 31009444. doi:10.1097/TA.0000000000002214

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。